FDA Rejects Ivonescimab, Demanding Survival Data Summit Did Not Have
FDA rejects Akeso and Summit's ivonescimab in EGFR-mutated NSCLC after HARMONi failed to show survival at primary analysis; Summit falls 15%, Akeso 22%.
TAG T-7165 · 577 words on the filing

Summary of findings
- FDA rejected ivonescimab plus chemo in EGFR-mutated NSCLC; progression delay alone did not support a positive benefit-risk profile.
- HARMONi slowed progression or death by more than two months but showed no clear survival benefit at primary analysis.
- Summit shares fell 6% Friday and 15% Monday; Akeso's Hong Kong-listed shares fell 22% Monday.
- Head-to-head data of ivonescimab-chemo versus Keytruda-chemo in first-line lung cancer expected by end of year.
- Akeso licensed most rights to ivonescimab to Summit in 2022.
The FDA has rejected ivonescimab, the PD-1/VEGF bispecific antibody from Akeso and Summit Therapeutics, on the grounds that delayed tumor progression alone does not support a positive benefit-risk profile without a survival benefit at primary analysis. Summit disclosed the decision in a Sunday statement from its Miami headquarters.
The company had sought approval of ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer after progression on a targeted therapy. The filing rested on the HARMONi study, which tested the ivonescimab-chemotherapy combination against chemotherapy alone.
What did HARMONi actually show?
- The regimen slowed disease progression or death by more than two months.
- The primary analysis did not show a clear survival benefit.
- An after-the-fact evaluation, which included more participants enrolled from sites outside Asia, did reveal a survival benefit.
- The FDA declined to accept those post-hoc results.
Summit argued in its statement that regulators held the drug to a higher bar than other available medicines for EGFR-mutated lung cancer, noting that no other FDA-approved regimen has demonstrated a survival benefit in this treatment setting.
"We are disappointed for patients and their families awaiting additional treatment options in this setting," said Summit chairman and co-CEO Robert Duggan. "We chose to pursue an ivonescimab regimen here based on the opportunity to provide another treatment option to help patients in need. In doing so, we believe the global HARMONi study provided the for a treatment option that these patients needed."
How did the market respond?
Summit shares fell 6% on Friday, ahead of the FDA's decision deadline, and dropped another 15% on Monday. Akeso, which invented the drug and licensed most rights to Summit in 2022, saw its Hong Kong-traded shares fall 22% on Monday.
Ivonescimab ranks among the most closely watched assets in oncology. In 2024, a trial result showed it had beaten Merck's Keytruda in lung cancer, triggering a wave of investment in drugs that target PD-1 and VEGF together. The drug has since met many investor expectations, but a substantial share of the supporting data comes from studies run in China, and critics have argued that subtle differences in trial design and enrollment criteria may have inflated its apparent effect.
What does the rejection change for the filing strategy?
Wall Street was split before the verdict. TD Cowen's Tyler Van Buren had argued the eventual survival benefit should suffice for approval; Leerink Partners' Daina Graybosch had pointed to an explicit FDA statement that the benefit had to be detected at the study's primary analysis.
Van Buren called the decision "disappointing" but "consistent with the high bar FDA had previously communicated" in a Sunday client note. Graybosch wrote that the verdict shows survival findings from other China-only studies could not overcome what was observed in the global HARMONi trial — and that Summit may therefore be unable to rely on the China-based HARMONi-6 study to support a lung cancer filing in a different setting going forward.
Both analysts flagged the more consequential readout approaching fast. By the end of the year, Summit and Akeso expect results from a study testing ivonescimab plus chemotherapy against Keytruda plus chemotherapy in first-line lung cancer. Van Buren wrote that the rejection "should have limited read-through to the larger ... opportunity."
For filing teams, the message is direct: a post-hoc survival signal cannot substitute for a primary-analysis endpoint at the FDA.
via BioPharma Dive (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
22 articles
Linked filings
- C-7166
- C-4460
- P-9899
- K-1065
- C-6506